

Table SI. Inclusion of literatures information.

Study	Population	Research period	No. of patients	Test research	lncRNA	State	Prognosis index	HR	Ref.
Chen <i>et al</i> , 2019	China	2010-2013	279	RT-qPCR	HOTAIR	Upregulation	OS	KM curve	20
Dai <i>et al</i> , 2022	China		56	RT-qPCR	FAM225B	Upregulation	OS	KM curve	21
Du <i>et al</i> , 2021	China		65	RT-qPCR	EPB41L4A-AS2	Downregulation	OS	KM curve	43
Gao <i>et al</i> , 2019	China		84	RT-qPCR	HOXC13-AS	Upregulation	OS	KM curve	22
Guo <i>et al</i> , 2017	China		112	ISH	LINC0086	Downregulation	OS	KM curve	44
Guo <i>et al</i> , 2021	China	2010-2018	96	RT-qPCR	ANCR	Upregulation	OS, DFS	Article	23
He <i>et al</i> , 2018	China		94	ISH	PVT1	Upregulation	OS, RFS	KM curve	24
He <i>et al</i> , 2023	China		126	ISH/qPCR	LINC00173	Upregulation	OS, DFS	Article	40
Jia <i>et al</i> , 2019	China		72	RT-qPCR	PXN-AS1-L	Upregulation	OS	KM curve	25
Jiang <i>et al</i> , 2017	China		120	RT-qPCR	HULC	Upregulation	OS	KM curve	26
Liu <i>et al</i> , 2018	China	2011-2013	129	RT-qPCR	SNHG12	Upregulation	OS	KM curve	27
Liu <i>et al</i> , 2019	China		96	RT-qPCR	NEAT1	Upregulation	OS	KM curve	28
Luan <i>et al</i> , 2022	China		58	RT-qPCR	SNHG8	Upregulation	OS	KM curve	37
Miao <i>et al</i> , 2023	China	2014-2018	100	RT-qPCR	LINC00173	Upregulation	RFS	KM curve	39
Nie <i>et al</i> , 2013	China		160	ISH/qPCR	HOTAIR	Upregulation	OS, DFS, RFS	KM curve	29
Sun <i>et al</i> , 2015	China		68	RT-qPCR	LET	Downregulation	OS, RFS	KM curve	45
Sun <i>et al</i> , 2022	China		73	RT-qPCR	CRNDE	Upregulation	OS	KM curve	36
Tang <i>et al</i> , 2020	China		101	ISH	AATBC	Upregulation	OS	KM curve	30
Tian <i>et al</i> , 2023	China	2008-2010	121	RT-qPCR	Lnc-MRPL39-2:1	Upregulation	OS	Article	38
Wan <i>et al</i> , 2022	China		121	RT-qPCR	TUBA4B	Downregulation	OS, RFS	KM curve	47
Wen <i>et al</i> , 2018	China		212	RT-qPCR	DANCR	Upregulation	OS, DFS	KM curve	31
Yang <i>et al</i> , 2021	China		83	RT-qPCR	HOTAIR	Upregulation	OS	KM curve	13
Yao <i>et al</i> , 2021	China		166	RT-qPCR	FOXP4-AS1	Upregulation	OS	KM curve	32
Zhang <i>et al</i> , 2019	China	1999-2001	107	RT-qPCR	NKILA	Downregulation	OS, DFS, RFS	KM curve	46
Zheng <i>et al</i> , 2022	China		126	FISH/ qPCR	HCG11	Upregulation	OS	KM curve	35
Zheng <i>et al</i> , 2023	China		214	RT-qPCR	LINC00839	Upregulation	OS, DFS	Article	41
Zhou <i>et al</i> , 2020	China		130	ISH	RP11-624L4.1	Upregulation	OS, DFS	Article	33
Zhou <i>et al</i> , 2023	China		58	RT-qPCR	SNHG4	Upregulation	OS	KM curve	42
Zou <i>et al</i> , 2016	China	2009-2012	88	RT-qPCR	ANRIL	Upregulation	OS, DFS	Article	34

HR, hazard ratio; OS, overall survival; DFS, disease-free survival; RFS, relapse-free survival; RT-qPCR, reverse transcription-quantitative PCR; ISH, *in situ* hybridization; KM, Kaplan-Meier.

Table SII. The relationship between upregulation of lncRNAs' expression and prognosis of patients with nasopharyngeal carcinoma (subgroup analysis).

Study	Gene	Survival index	Combined HR	95% CI	Z	P-value	Ref.
Chen <i>et al</i> , 2019	HOTAIR	OS	1.95	1.02-3.73	2.03	0.04	20
Dai, <i>et al</i> , 2022	FAM225B	OS	2.34	0.48-11.45	1.05	0.29	21
Gao <i>et al</i> , 2019	HOXC13-AS	OS	1.49	0.32-7.02	0.51	0.61	22
Guo, <i>et al</i> , 2021	ANCR	DFS	1.43	0.84-2.43	1.33	0.18	23
		OS	1.27	0.69-2.33	0.77	0.44	
He <i>et al</i> , 2018	PVT1	OS	1.57	0.69-3.57	1.07	0.28	24
		RFS	1.43	0.77-2.68	1.13	0.26	
He <i>et al</i> , 2023	LINC00173	DFS	1.68	1.01-2.80	2.00	0.05	40
		OS	2.18	1.31-3.63	3.00	0.003	
Jia <i>et al</i> , 2019	PXN-AS1-L	OS	1.54	0.28-8.46	0.49	0.62	25
Jiang <i>et al</i> , 2017	HULC	OS	1.32	0.40-4.37	0.46	0.65	26
Liu <i>et al</i> , 2018	SNHG12	OS	3.00	1.51-5.97	3.14	0.002	27
Liu <i>et al</i> , 2019	NEAT1	OS	2.53	1.35-4.75	2.91	0.004	28
Luan <i>et al</i> , 2022	SNHG8	OS	1.40	0.19-10.58	0.33	0.74	37
Miao <i>et al</i> , 2023	LINC00173	RFS	1.95	0.01-521.08	0.24	0.81	39
		DFS	1.31	0.70-2.45	0.84	0.4	29
Nie <i>et al</i> , 2013	HOTAIR	OS	1.35	0.67-2.73	0.83	0.4	
		RFS	1.48	0.79-2.77	1.22	0.22	
Sun <i>et al</i> , 2022	CRNDE	OS	1.86	0.59-5.91	1.05	0.29	36
Tang <i>et al</i> , 2020	AATBC	OS	1.22	0.60-2.47	0.56	0.58	30
Tian <i>et al</i> , 2023	Lnc-MRPL39-2:1	OS	3.25	1.77-5.98	3.81	0.0001	38
		DFS	1.22	0.67-2.24	0.65	0.52	31
Wen, <i>et al</i> , 2018	DANCR	OS	1.19	0.57-2.45	0.46	0.65	
Yang <i>et al</i> , 2021	HOTAIR	OS	0.86	0.29-2.53	0.27	0.79	13
Yao <i>et al</i> , 2021	FOXP4-AS1	OS	3.22	1.72-6.03	3.66	0.0003	32
Zheng <i>et al</i> , 2022	HCG11	OS	3.71	1.21-11.33	2.30	0.02	35
Zheng <i>et al</i> , 2023	LINC00839	DFS	2.10	1.34-3.29	3.22	0.001	41
		OS	1.90	1.21-2.98	2.78	0.005	
Zhou, <i>et al</i> , 2020	RP11-624L4.1	DFS	1.3	0.64-2.63	0.72	0.47	33
		OS	3.74	1.40-9.97	2.64	0.008	
Zhou <i>et al</i> , 2023	SNHG4	OS	2.32	0.82-6.55	1.58	0.11	42
Zou <i>et al</i> , 2016	ANRIL	DFS	2.05	1.21-3.49	2.67	0.008	34
		OS	4.35	1.37-13.82	2.49	0.01	

HR, hazard ratio; CI, confidence interval; OS, overall survival; DFS, disease-free survival; RFS, relapse-free survival.

Table SIII. Summarization of exclusion sensitivity analysis results of the relationship between upregulation of lncRNAs' expression and (T) stage of primary tumor in nasopharyngeal carcinoma.

Study	Heterogeneity test result		Meta-analysis result		Ref.
	I ²	P- value	OR (95% CI)	P- value	
No exclusion	58	0.001	1.96 (1.43-2.70)	0.0001	
Chen <i>et al</i> , 2019	61	0.0009	1.94 (1.37-2.74)	0.0002	20
Dai <i>et al</i> , 2022	58	0.002	1.88 (1.36-2.61)	0.0001	21
Gao <i>et al</i> , 2019	61	0.0009	1.97 (1.41-2.77)	0.0001	22
Guo <i>et al</i> , 2021	61	0.0009	1.98 (1.41-2.78)	0.0001	23
He <i>et al</i> , 2018	58	0.002	2.05 (1.48-2.84)	0.0001	24
Jia <i>et al</i> , 2019	61	0.0009	1.98 (1.42-2.78)	0.0001	25
Jiang, <i>et al</i> , 2017	37	0.07	1.80 (1.47-2.21)	0.00001	26
Liu <i>et al</i> , 2018	60	0.001	1.99 (1.42-2.80)	0.0001	27
Liu <i>et al</i> , 2019	56	0.004	2.07 (1.51-2.86)	0.00001	28
Miao <i>et al</i> , 2023	60	0.001	1.94 (1.40-2.68)	0.0001	39
Nie <i>et al</i> , 2013	61	0.0009	1.95 (1.38-2.78)	0.0002	29
Tang <i>et al</i> , 2020	56	0.004	2.07 (1.51-2.85)	0.00001	30
Tian <i>et al</i> , 2023	59	0.001	1.90 (1.36-2.65)	0.0002	38
Wen <i>et al</i> , 2018	53	0.007	2.10 (1.54-2.86)	0.00001	31
Yao <i>et al</i> , 2021	59	0.002	1.89 (1.35-2.65)	0.0002	32
Zhou <i>et al</i> , 2020	59	0.001	1.90 (1.36-2.65)	0.0002	33
Zou <i>et al</i> , 2016	61	0.0009	1.98 (1.41-2.77)	0.0001	34

lncRNAs, long non-coding RNAs; OR, odds ratio; CI, confidence interval.

Table SIV. Summarization of exclusion sensitivity analysis results of the relationship between upregulation of lncRNAs’ expression and regional lymph node metastasis (N) stage.

Study	Heterogeneity test result		Meta-analysis result		Ref.
	I ²	P- value	OR (95% CI)	P- value	
No exclusion	69	0.00001	1.78 (1.32-2.40)	0.0002	
Chen <i>et al</i> , 2019	70	0.00001	1.76 (1.27-2.43)	0.0006	20
Dai <i>et al</i> , 2021	70	0.00001	1.77 (1.29-2.41)	0.0003	21
Gao <i>et al</i> , 2019	66	0.0001	1.88 (1.40-2.52)	0.0001	22
Guo <i>et al</i> , 2021	69	0.00001	1.72 (1.27-2.34)	0.0005	23
He <i>et al</i> , 2018	65	0.0001	1.89 (1.41-2.52)	0.0001	24
He <i>et al</i> , 2023	69	0.00001	1.82 (1.32-2.50)	0.0002	40
Jia <i>et al</i> , 2019	70	0.00001	1.74 (1.28-2.36)	0.0005	25
Jiang <i>et al</i> , 2017	59	0.0004	1.63 (1.25-2.13)	0.0004	26
Liu <i>et al</i> , 2018	70	0.00001	1.79 (1.30-2.45)	0.0003	27
Liu <i>et al</i> , 2019	69	0.00001	1.72 (1.27-2.34)	0.0005	28
Miao <i>et al</i> , 2023	70	0.00001	1.82 (1.34-2.48)	0.0001	39
Nie <i>et al</i> , 2013	69	0.00001	1.74 (1.27-2.39)	0.0006	29
Tang <i>et al</i> , 2020	69	0.00001	1.83 (1.35-2.50)	0.0001	30
Tian <i>et al</i> , 2023	68	0.00001	1.70 (1.26-2.30)	0.0006	38
Wen <i>et al</i> , 2018	69	0.00001	1.82 (1.33-2.50)	0.0002	31
Yang <i>et al</i> , 2021	70	0.00001	1.74 (1.28-2.38)	0.0005	13
Yao <i>et al</i> , 2021	69	0.00001	1.82 (1.33-2.50)	0.0002	32
Zheng <i>et al</i> , 2022	70	0.00001	1.74 (1.27-2.38)	0.0005	35
Zheng <i>et al</i> , 2023	67	0.0001	1.87 (1.39-2.52)	0.0001	41
Zhou <i>et al</i> , 2020	69	0.00001	1.73 (1.27-2.37)	0.0005	33
Zou <i>et al</i> , 2016	70	0.00001	1.79 (1.31-2.44)	0.0003	34
lncRNAs, long non-coding RNAs; OR, odds ratio; CI, confidence interval.					

Table SV. Summarization of exclusion sensitivity analysis results of the relationship between upregulation of lncRNAs’ expression and distant metastasis (M) stage of nasopharyngeal carcinoma.

Study	Heterogeneity test result		Meta-analysis result		Ref.
	I ²	P-value	OR (95% CI)	P-value	
No exclusion	73	0.00001	1.47 (0.94-2.31)	0.09	
Chen <i>et al</i> , 2019	74	0.00001	1.46 (0.91-2.35)	0.12	20
Dai <i>et al</i> , 2021	72	0.00001	1.38 (0.87-2.18)	0.17	21
Gao <i>et al</i> , 2019	70	0.00001	1.60 (1.02-2.50)	0.04	22
He <i>et al</i> , 2018	74	0.00001	1.47 (0.93-2.32)	0.10	24
Jia <i>et al</i> , 2019	73	0.00001	1.43 (0.90-2.26)	0.13	25
Jiang <i>et al</i> , 2017	72	0.00001	1.38 (0.88-2.17)	0.16	26
Liu <i>et al</i> , 2018	74	0.00001	1.46 (0.91-2.37)	0.12	27
Liu <i>et al</i> , 2019	73	0.00001	1.42 (0.90-2.23)	0.13	28
Luan <i>et al</i> , 2022	67	0.00001	1.63 (1.07-2.49)	0.02	37
Nie <i>et al</i> , 2013	70	0.00001	1.59 (1.01-2.49)	0.04	29
Sun <i>et al</i> , 2022	72	0.00001	1.38 (0.87-2.18)	0.17	36
Tang <i>et al</i> , 2020	74	0.00001	1.49 (0.94-2.36)	0.09	30
Tian <i>et al</i> , 2023	74	0.00001	1.49 (0.93-2.38)	0.10	38
Wen <i>et al</i> , 2018	72	0.00001	1.41 (0.88-2.25)	0.15	31
Yang <i>et al</i> , 2021	73	0.00001	1.41 (0.88-2.25)	0.15	13
Yao <i>et al</i> , 2021	72	0.00001	1.56 (0.98-2.49)	0.06	32
Zheng <i>et al</i> , 2022	74	0.00001	1.49 (0.92-2.40)	0.11	35
Zheng <i>et al</i> , 2023	73	0.00001	1.45 (0.89,2.37)	0.13	41
Zhou <i>et al</i> , 2020	71	0.00001	1.35 (0.86-2.11)	0.19	33
Zhou <i>et al</i> , 2023	73	0.00001	1.55 (0.97-2.48)	0.07	42
Zou <i>et al</i> , 2016	74	0.00001	1.52 (0.94-2.45)	0.08	34
lncRNAs, long non-coding RNAs; OR, odds ratio; CI, confidence interval.					

Table SVI. Summarization of exclusion sensitivity analysis results of the relationship between upregulation of lncRNAs’ expression and clinical stage of nasopharyngeal carcinoma.

Study	Heterogeneity test result		Meta-analysis result		Ref.
	I ²	P-value	OR (95% CI)	P-value	
No exclusion	85	0.00001	3.21 (1.91-5.38)	0.00001	
Dai <i>et al</i> , 2021	85	0.00001	3.11 (1.82-5.29)	0.0001	21
Gao <i>et al</i> , 2019	86	0.00001	3.21 (1.86-5.52)	0.0001	22
Guo <i>et al</i> , 2021	86	0.00001	3.17 (1.85-5.43)	0.0001	23
He <i>et al</i> , 2018	84	0.00001	3.59 (2.16-5.98)	0.00001	24
Jia <i>et al</i> , 2019	86	0.00001	3.22 (1.87-5.53)	0.0001	25
Jiang <i>et al</i> , 2017	82	0.00001	2.80 (1.73,4.53)	0.0001	26
Liu <i>et al</i> , 2018	86	0.00001	3.18 (1.84-5.50)	0.0001	27
Liu <i>et al</i> , 2019	86	0.00001	3.21 (1.86-5.53)	0.0001	28
Luan <i>et al</i> , 2022	85	0.00001	3.11 (1.83-5.31)	0.0001	37
Nie <i>et al</i> , 2013	86	0.00001	3.27 (1.88-5.68)	0.0001	29
Sun <i>et al</i> , 2022	86	0.00001	3.18 (1.85-5.46)	0.0001	36
Tang <i>et al</i> , 2020	85	0.00001	3.49 (2.07-5.90)	0.00001	30
Tian <i>et al</i> , 2023	84	0.00001	2.99 (1.78,5.04)	0.0001	38
Wen <i>et al</i> , 2018	83	0.00001	3.48 (2.06-5.88)	0.00001	31
Yang <i>et al</i> , 2021	86	0.00001	3.24 (1.88-5.58)	0.0001	13
Yao <i>et al</i> , 2021	81	0.00001	3.58 (2.21,5.80)	0.00001	32
Zheng <i>et al</i> , 2022	84	0.00001	2.90 (1.75-4.82)	0.0001	35
Zhou <i>et al</i> , 2020	86	0.00001	3.23 (1.86-5.61)	0.0001	33
Zhou <i>et al</i> , 2023	86	0.00001	3.18 (1.86-5.44)	0.0001	42
Zou <i>et al</i> , 2016	85	0.00001	3.14 (1.84-5.37)	0.0001	34
lncRNAs, long non-coding RNAs; OR, odds ratio; CI, confidence interval.					

Table SVII. Summarization of Begg test and Egger test results in the upregulated lncRNAs’ expression.

Study	Begg test		Egger test	
	Z	P- value	t	P-value
Relationship between upregulation of lncRNAs expression and patient's gender	0.37	0.710	0.26	0.800
Relationship between upregulation of lncRNAs expression and primary tumor (T) stage	0.21	0.837	0.12	0.906
Relationship between upregulation of lncRNAs expression and regional lymph node (N) stage	0.75	0.450	0.63	0.539
Relationship between upregulation of lncRNAs expression and tumor distant metastasis (M) stage	0.75	0.450	0.98	0.337
Relationship between upregulation of lncRNAs expression and tumor clinical stage	2.76	0.006	3.11	0.006
Relationship between upregulation of lncRNAs expression and overall survival rates	0.74	0.460	-0.26	0.796
lncRNAs, long non-coding RNAs.				

Table SVIII. Data summary of lncRNAs' expression.

Study	OS		DFS		RFS		Ref.
	lnHR	selnHR	lnHR	selnHR	lnHR	selnHR	
Chen <i>et al</i> ,2019	0.67	0.33					20
Dai <i>et al</i> , 2022	0.85	0.81					21
Gao <i>et al</i> , 2019	0.4	0.79					22
Guo <i>et al</i> , 2021	0.24	0.31	0.36	0.27			23
He <i>et al</i> , 2018	0.45	0.42			0.36	0.32	24
He <i>et al</i> , 2023	0.78	0.26	0.52	0.26			40
Jia <i>et al</i> , 2019	0.43	0.87					25
Jiang <i>et al</i> , 2017	0.28	0.61					26
Liu <i>et al</i> , 2018	1.1	0.35					27
Liu <i>et al</i> , 2019	0.93	0.32					28
Luan <i>et al</i> , 2022	0.34	1.03					37
Miao <i>et al</i> , 2023	0.3	0.36			0.67	2.85	39
Nie <i>et al</i> , 2013	0.62	0.59	0.27	0.32	0.39	0.32	29
Sun <i>et al</i> , 2022	0.2	0.36					36
Tang <i>et al</i> , 2020	1.18	0.31					30
Tian <i>et al</i> , 2023	0.17	0.37					38
Wen <i>et al</i> , 2018	-0.15	0.55	0.2	0.31			31
Yang <i>et al</i> , 2021	1.17	0.32					13
Yao <i>et al</i> , 2021	1.31	0.57					32
Zheng <i>et al</i> , 2022	0.64	0.23					35
Zheng <i>et al</i> , 2023	1.32	0.5	0.74	0.23			41
Zhou <i>et al</i> , 2020	0.84	0.53	0.26	0.36			33
Zhou <i>et al</i> , 2023	1.47	0.59					42
Zou <i>et al</i> , 2016	0.67	0.33	0.72	0.27			34

lncRNAs, long non-coding RNAs; OS, overall survival; DFS, disease-free survival; RFS, relapse-free survival.

Table SX. Pertinent data summary of lncRNAs’ expression.

Study	Sex		Clinical stage		Primary tumor		Local lymph node		Distant metastasis		Ref.
	Male n (N)	Female n (N)	I-II n (N)	III-IV n (N)	T1-T2 n (N)	T3-T4 n (N)	N0-N1 n (N)	N2-N3 n (N)	M0 n (N)	M1 n (N)	
Chen <i>et al</i> , 2019	132 (220)	35 (59)			18 (42)	149 (237)	80 (154)	87 (125)	149 (254)	18 (25)	20
Dai <i>et al</i> , 2022	17 (32)	11 (24)	7 (26)	21 (30)	10 (30)	18 (26)	12 (29)	16 (27)	11 (32)	17 (24)	21
Gao <i>et al</i> , 2019	29 (55)	13 (29)	12 (36)	30 (48)	17 (40)	25 (44)	17 (27)	25 (57)	29 (47)	13 (37)	22
Guo <i>et al</i> , 2021	35 (67)	13 (29)	6 (24)	42 (72)	27 (60)	21 (36)	13 (40)	35 (56)			23
He <i>et al</i> , 2018	51 (78)	9 (16)	18 (22)	38 (68)	38 (61)	17 (28)	28 (39)	27 (50)	54 (89)	1 (1)	24
He <i>et al</i> , 2023	88 (167)	19 (47)					52 (110)	55 (104)			40
Jia <i>et al</i> , 2019	23 (49)	13 (23)	12 (34)	24 (38)	21 (46)	15 (26)	19 (47)	17 (25)	32 (67)	4 (5)	25
Jiang <i>et al</i> , 2017	56 (80)	22 (40)	7 (41)	71 (79)	17 (48)	61 (72)	21 (55)	57 (65)	62 (103)	16 (17)	26
Liu <i>et al</i> , 2018	30 (58)	32 (71)	31 (84)	31 (45)	36 (82)	26 (47)	40 (90)	22 (39)	44 (98)	18 (31)	27
Liu <i>et al</i> , 2019	26 (60)	22 (36)	15 (44)	33 (52)	31 (60)	17 (36)	19 (52)	29 (44)	44 (92)	4 (4)	28
Luan <i>et al</i> , 2022	15 (28)	14 (30)	7 (26)	22 (32)					24 (35)	5 (23)	37
Miao <i>et al</i> , 2023	16 (89)	2 (11)			0 (11)	18 (89)	5 (26)	13 (74)			39
Nie <i>et al</i> , 2013	65 (109)	26 (51)	19 (46)	72(114)	40 (83)	51 (77)	36 (79)	55 (81)	32 (45)	59 (115)	29
Sun <i>et al</i> , 2022	21 (40)	16 (33)	9 (29)	28 (44)					11 (34)	26 (39)	36
Tang <i>et al</i> , 2020	50 (84)	6 (17)	15 (24)	37 (72)	38 (68)	14 (28)	22 (40)	30 (56)	51 (94)	1 (2)	30
Tian <i>et al</i> , 2023	64 (87)	28 (35)	20 (43)	72 (79)	26 (43)	64 (77)	35 (57)	57 (65)	77 (103)	15 (19)	38
Wen <i>et al</i> , 2018	105 (164)	33 (48)	85 (127)	53 (85)	21 (29)	117 (183)	77 (121)	61 (91)	101 (167)	37 (45)	31
Yang <i>et al</i> , 2021	27 (47)	19 (36)	11 (28)	35 (55)			14 (34)	32 (49)	9 (25)	37 (58)	13
Yao <i>et al</i> , 2021	62 (120)	21 (46)	51 (86)	32 (80)	42 (105)	41 (61)	43 (89)	40 (77)	75 (144)	8 (22)	32
Zheng <i>et al</i> , 2022	29 (81)	22 (45)	22 (93)	29 (33)			29 (87)	22 (39)	39 (100)	12 (26)	35
Zheng <i>et al</i> , 2023	83 (163)	24(51)					22(38)	85 (176)	70 (154)	37 (60)	41
Zhou <i>et al</i> , 2020	47 (99)	19 (31)	27 (70)	39 (60)	35(85)	31(45)	29(73)	37 (57)	48 (109)	18 (21)	33
Zhou <i>et al</i> , 2023	19 (36)	13 (22)	13 (32)	19 (26)					14(33)	18 (58)	42
Zou <i>et al</i> , 2016	38 (70)	6 (18)	5 (22)	39 (66)	22 (50)	22 (38)	16 (37)	28 (51)	29 (57)	15 (31)	34

lncRNAs, long non-coding RNAs; n, sample size of lncRNAs high expression; N, sample size of lncRNAs total expression.

Table SXI. Pertinent data summary of downregulation of lncRNAs expression.

Study	Sex		Clinical stage		Primary tumor		Local lymph node		Distant metastasis		Ref.
	Male	Female	I-II	III-IV	T1-T2	T3-T4	N0-N1	N2-N3	M0	M1	
	n (N)	n (N)	n (N)	n (N)	n (N)	n (N)	n (N)	n (N)	n (N)	n (N)	
Du <i>et al</i> , 2021	25 (48)	8 (17)	17 (27)	16 (38)	11 (17)	22 (48)	20 (31)	13 (34)	27 (51)	6 (14)	43
Guo <i>et al</i> , 2017	23(56)	21 (56)	32 (63)	12 (49)					28 (53)	16 (59)	44
Sun <i>et al</i> , 2015	21(47)	13 (21)	18 (27)	16 (41)	22 (33)	12 (35)			30 (54)	4 (14)	45
Wan <i>et al</i> , 2022	21(50)	22 (41)	32 (52)	11 (39)	21 (48)	22 (43)	31 (49)	12 (42)	22 (47)	21 (44)	47
Zhang <i>et al</i> , 2019	34(85)	10 (22)	27 (47)	17 (60)	33 (65)	11 (42)	36 (81)	8 (26)	38 (80)	6 (27)	46

lncRNAs, long non-coding RNAs; n, sample size of lncRNAs high expression; N, sample size of lncRNAs total expression.